4zyi
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| + | |||
==Discovery of NVP-CGM097 - a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical trials in p53wt tumors: Hdm2 (MDM2) complexed with cpd2== | ==Discovery of NVP-CGM097 - a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical trials in p53wt tumors: Hdm2 (MDM2) complexed with cpd2== | ||
| - | <StructureSection load='4zyi' size='340' side='right' caption='[[4zyi]], [[Resolution|resolution]] 1.67Å' scene=''> | + | <StructureSection load='4zyi' size='340' side='right'caption='[[4zyi]], [[Resolution|resolution]] 1.67Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[4zyi]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4ZYI OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ZYI FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[4zyi]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4ZYI OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ZYI FirstGlance]. <br> |
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=4TH:(S)-7-((R)-SEC-BUTOXY)-1-(4-CHLOROPHENYL)-6-METHOXY-2-(4-(METHYL(PYRIDIN-4-YLMETHYL)AMINO)PHENYL)-1,2-DIHYDROISOQUINOLIN-3(4H)-ONE'>4TH</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=4TH:(S)-7-((R)-SEC-BUTOXY)-1-(4-CHLOROPHENYL)-6-METHOXY-2-(4-(METHYL(PYRIDIN-4-YLMETHYL)AMINO)PHENYL)-1,2-DIHYDROISOQUINOLIN-3(4H)-ONE'>4TH</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene></td></tr> | ||
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4zyi FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4zyi OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4zyi RCSB], [http://www.ebi.ac.uk/pdbsum/4zyi PDBsum]</span></td></tr> | + | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">MDM2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> |
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4zyi FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4zyi OCA], [http://pdbe.org/4zyi PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4zyi RCSB], [http://www.ebi.ac.uk/pdbsum/4zyi PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4zyi ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Disease == | == Disease == | ||
| Line 18: | Line 20: | ||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
</div> | </div> | ||
| + | <div class="pdbe-citations 4zyi" style="background-color:#fffaf0;"></div> | ||
| + | |||
| + | ==See Also== | ||
| + | *[[MDM2|MDM2]] | ||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
| + | [[Category: Human]] | ||
| + | [[Category: Large Structures]] | ||
[[Category: Kallen, J]] | [[Category: Kallen, J]] | ||
[[Category: Cell cycle]] | [[Category: Cell cycle]] | ||
[[Category: Inhibitor complex]] | [[Category: Inhibitor complex]] | ||
[[Category: Ppi with p53]] | [[Category: Ppi with p53]] | ||
Revision as of 08:35, 26 June 2019
Discovery of NVP-CGM097 - a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical trials in p53wt tumors: Hdm2 (MDM2) complexed with cpd2
| |||||||||||
